Merus NV « Terug naar discussie overzicht

Merus NV forum geopend

1.038 Posts, Pagina: « 1 2 3 4 5 6 ... 46 47 48 49 50 51 52 » | Laatste
Ron Kerstens
0
Met 110 mln erbij uit de emissie komt de cashpositie uit op bijna 450mln dollar. Ik ga er toch vanuit dat dit het laatste rondje was. Er staan nu 42,5 mln aandelen uit, 10 dollar cash per aandeel.

Koersval valt me mee, de emissiekoers wordt in elk geval nog niet gehaald.
Ron Kerstens
0
Ron Kerstens
0
De emissie op 28,50 sluit morgen, 9 nov, terwijl de koers nu op 27,50 staat. Vraag me af of dit wel een succes wordt, wellicht toch wat overvraagd. Ik heb wat bijgekocht op gem. 27,60.
Ron Kerstens
0
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual).

The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am GMT/3:00 am ET on the Investors page of the Company's website and remain available for a limited time.
DrBob
0
Goedemiddag, heeft iemand kunnen vinden of de emissie geslaagd is en wat die heeft opgeleverd; zodat we ook een idee hebben van de verwatering.. Hierover moet ze toch publiceren?
Ron Kerstens
0
Nee, er is nog geen bericht. Nu was de emissie wel underwritten zodat bij te weinig belangstelling de emissie gewoon door zou moeten gaan.
DrBob
0
RE: Result of “Public Offering” of Nov 4, 2021.
Hi xxx
Thanks for reaching out. You can find the closing details in the 424B5 filing here:
ir.merus.nl/sec-filings/sec-filing/42...
Best,
Xxx
Ron Kerstens
0
Begrijp dat toch niet goed. Dit is toch gewoon het prospektus ? Zegt verder niks over de uiteindelijke plaatsing, in het prospektus ia wel te lezen welke partijen voor hoeveel aandelen garant staan (underwritten). De emissie sloot op 9 nov, dus na deze publicatie.
fly like an eagle
0
December 6, 2021 at 6:42 AM EST
View PDF Version
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually.

“We are encouraged by the progress we are making with MCLA-145,” said Dr. Andrew Joe, Chief Medical Officer. “Patients have been treated at 8 dose levels with preliminary evidence of antitumor activity observed, as we continue to explore MCLA-145 as monotherapy.”

MCLA-145

The reported data are from the phase 1 open-label, multicenter dose escalation study, of bispecific antibody MCLA-145 in patients with solid tumors. The primary objective is to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) of MCLA-145 and to determine maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE).

Observations in the presentation include:

As of the data cutoff date of July 14, 2021, 34 patients with advanced or metastatic solid tumors with median age of 60.5 (range 27-81) years have been treated at 8 dose levels ranging from 0.4-75mg Q2W
Median (range) duration of treatment with MCLA 145 was approximately 6 (1–74) weeks
Reported adverse events (AEs) have been managed with drug interruption and/or administration of steroids in some patients
Treatment-emergent AEs (TEAEs) occurred in 33 patients (97.1%); treatment-related TEAEs occurred in 23 patients (67.6%), most commonly fatigue (n=6, 17.6%) and decreased neutrophil count (n=6, 17.6%)
DLTs defined as within 28 days from the first infusion occurred in 4 patients (11.8%)
Laboratory alanine transaminase/aspartate transaminase (ALT/AST) elevations of any grade were observed in 15 patients (44.1%), with grade =3 ALT/AST elevations in 6 patients (17.6%)
Preliminary evidence of antitumor activity has been observed at doses =25 mg biweekly
Peripheral blood shows robust T-cell activation, including activation of cytotoxic CD8+ cells and cytokines, across the 10 to 75 mg biweekly dosing range
Further evaluation of optimal dose and efficacy in PD-L1+ tumors is planned.
The phase 1 clinical trial of MCLA-145 consists of a dose escalation phase, followed by a planned dose expansion phase. MCLA-145 is the first drug candidate co-developed under Merus’ global collaboration and license agreement with Incyte, which permits the development and commercialization of up to 11 bispecific and monospecific antibodies from the Merus Biclonics® platform. Merus retains full rights to develop and commercialize MCLA-145, if approved, in the United States; and Incyte holds full rights to develop and commercialize MCLA-145 outside the United States.
fly like an eagle
0
December 10, 2021 at 8:00 AM EST
View PDF Version
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met

- The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1

- Validates the potential of zenocutuzumab in additional indications outside NRG1 fusions

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), presented clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who had progressed on anti-HER2 antibody drug conjugates (ADC), at the San Antonio Breast Cancer Symposium in San Antonio, Texas.

Andrew Joe, Chief Medical Officer at Merus, said, “We are pleased to present the final analysis of the triplet Zeno combination which has demonstrated clinically meaningful activity in heavily pretreated patients with HER2+/amplified MBC. We are encouraged by Zeno’s potential to be active in indications outside NRG1 fusion cancers, opening opportunities for potential collaborations in these areas.”

The reported data are from the completed phase 2 study, designed to explore the efficacy of a triplet combination of Zeno plus trastuzumab and vinorelbine in MBC patients (NCT03321981). Preliminary results for patients treated with the triplet regimen were presented at the American Society of Clinical Oncology 2020 Annual Meeting. The combination was observed to be well-tolerated in the run-in cohort and the cohort was expanded. The primary endpoint of the study was clinical benefit rate (CBR) at 24 weeks of 45%. Updated results from the cohort expansion are presented here:

At the efficacy data cut-off, March 31, 2021, 39 patients, with a median age of 57 and with a median number of five prior therapies, had received the Zeno-based triplet combination, 4 of whom were ongoing. All patients had completed at least 6 months of treatment or discontinued
37 patients with locally confirmed HER2 overexpression (IHC 3+ or IHC 2+/FISH-positive) were evaluable for antitumor activity
The clinical benefit rate (CBR: complete response + partial response + stable disease =24 weeks) per investigator assessment was 49% (18/37 patients; 90% CI 34 - 63)
Confirmed responses (per investigator) were reported in 10 patients, including 2 patients with complete response (CR)
Median duration of response was 4.2 months (90% CI 2.8 - 12.4), including 2 patients with CR lasting 4.2 and 7.2+ months, and 8 patients with partial responses (PR) lasting from 2.6 to 12.4 months
Median progression-free survival was 5.5 months (90% CI 4.1 - 5.6); 7 patients (19%) were censored. Estimated overall survival rates at 12 and 24 months were 73% and 61%, respectively
The combination was observed to be well tolerated, with AEs primarily related to chemotherapy
As previously reported, with completion of this phase 2 trial, Merus does not have plans to advance into a phase 3 clinical trial in metastatic breast cancer in the absence of a partner. The company continues to focus on the eNRGy trial to potentially support a BLA submission seeking a tumor agnostic indication for Zeno in patients with previously treated NRG1+ cancers.
Beursgeslagen
0
Voormalig Novartis Oncology lead aan boord van Merus. Mooie vangst voor Merus. Overname dit jaar door bv Novartis niet ondenkbaar. Heb vaker dit soort moves gezien waarna een overname volgde.
fly like an eagle
0
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
January 25, 2022 at 4:30 PM EST
View PDF Version
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology.

“Shannon will be instrumental in advancing Merus’ mission to become a commercial-stage company, further advancing the strategy for our lead clinical program, zenocutuzumab for neuregulin 1 fusion cancer and developing our commercial approach for our pipeline of innovative multispecific antibody product candidates,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “Her leadership and depth of experience in launching products, managing partnerships, and delivering sustained performance in highly competitive oncology markets will be a great asset to our organization.”

Ms. Campbell will join Merus as Executive Vice President & Chief Commercial Officer in February to lead the commercial strategy for the most advanced clinical candidate, zenocutuzumab (Zeno), as well as Merus’ robust pipeline of multispecific product candidates in development. This includes petosemtamab (MCLA-158), currently under investigation in second-line head and neck squamous cell carcinoma; MCLA-145, under investigation for solid tumors; and MCLA-129, under investigation for patients with lung and other solid tumors, particularly those that do not respond to EGFR inhibitors. Merus holds global rights to all four clinical candidates, apart from MCLA-129, for which Merus licensed to Betta Pharmaceuticals the exclusive right to develop and commercialize in China.

Ms. Campbell brings over 25 years of pharmaceutical commercialization experience and joins Merus from Novartis Pharmaceuticals, where she led Novartis’s U.S. Oncology Solid Tumor Franchise and was responsible for a broad portfolio of therapies in oncology and rare diseases. Prior to Novartis, Ms. Campbell was with Bayer HealthCare Pharmaceuticals, where she was instrumental in helping to build, launch and lead Bayer’s U.S. Oncology business.

“I am excited to join Merus at this pivotal time,” said Ms. Campbell. “The Merus pipeline of clinical-stage assets has the potential to offer meaningful benefit to patients, and I look forward to building and leading the commercial strategy for these programs.”

Merus also announced today that Incyte (Nasdaq: INCY) has elected to opt-out of its ex-U.S. development of MCLA-145, restoring full global rights to Merus. MCLA-145 is currently enrolling a global, phase 1, open-label, single-agent clinical trial evaluating MCLA-145 in patients with solid tumors. The trial consists of a dose escalation phase, followed by a planned dose expansion phase. Merus is also planning to evaluate the combination of MCLA-145 with a PD-1 blocking antibody.

"Regaining worldwide rights to MCLA-145 opens up new possibilities for Merus," said Dr. Lundberg. "We remain committed to continuing the development of MCLA-145 to explore the potential of this compound as monotherapy, as well as in combination, to address the high unmet medical need for patients with solid tumors. We look forward to the further progress and continued success of our other joint projects in research and development with Incyte under this collaboration.”

Under the terms of a 2017 Collaboration and License Agreement (“Agreement”) between Merus and Incyte, Incyte received ex-U.S. rights to MCLA-145. Incyte’s opt-out of ex-U.S. rights to MCLA-145 provides Merus the exclusive right to develop and commercialize potential MCLA-145 products globally. As part of the Agreement, Incyte will continue to support the program for a limited time while ex-U.S. activities are transitioned to Merus, and Incyte will also retain a right to a residual royalty of up to 4% on sales of future commercialization of MCLA-145, if approved.

Additionally, per the Agreement, the parties will continue to collaborate on the development and commercialization of up to ten bispecific or monospecific antibody programs. Merus also has the option to co-fund development of product candidates arising from two programs. For any program for which Merus exercises its co-development option, Merus would be responsible for 35 percent of global development costs in exchange for a 50 percent share of U.S. profits and losses and tiered royalties ranging from 6 to 10 percent on ex-U.S. sales by Incyte for these programs. Merus also has the right to elect to provide up to 50 percent of detailing activities for product candidates arising from one of these programs in the U.S.
DrBob
0
Iemand enig idee wat de oorzaak is van deze extreme daling de laatste dagen? Normaal weet Merus idd aardig stand te houden..
fly like an eagle
0
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
April 25, 2022 at 8:00 AM EDT
View PDF Version
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced publication of a preclinical report on petosemtamab (Peto, MCLA-158: LGR5 x EGFR Biclonics®) in the journal Nature Cancer. The publication will be available at 11:00 a.m. ET today. The report describes the use of the company’s Biclonics® platform to perform a large-scale functional screen of bispecific antibodies resulting in selection of Peto, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G protein-coupled receptor (LGR5). Peto displayed potent growth inhibition of colorectal cancer (CRC) organoids, blockade of metastasis initiation and tumor outgrowth in preclinical models of different tumor types. Peto specifically triggered EGFR degradation in organoids expressing LGR5, while showing minimal toxicity towards normal LGR5-expressing organoids.

In October 2021, Merus reported early, interim clinical data in an ongoing trial of Peto in patients with head and neck squamous cell carcinoma (HNSCC).

“This publication demonstrates the potential of our Biclonics® platform to generate large numbers of diverse panels of antibodies, undertake high throughput functional screening of in-format bispecifics, and identify drug candidates that possess specific biology and characteristics for therapeutic applications,” said Cecile Geuijen, Ph.D., Senior Vice President and Chief Scientific Officer. “We are encouraged by the preclinical and clinical data we have obtained to date, and look forward to the further clinical development of Peto.”

The results published in Nature Cancer further describe Peto’s results in preclinical models of solid tumors, including the following highlights:

Peto exhibits unique therapeutic properties such as potent growth inhibition of KRAS mutant CRC organoids, blockade of metastasis initiation, and inhibition of tumor outgrowth in preclinical models of different tumor types
Peto shows superior growth inhibition relative to cetuximab, an EGFR inhibitor used for treatment of metastatic CRC and HNSCC, in subcutaneous xenografts generated from inoculation of C31M, a patient-derived CRC organoid bearing a KRAS G12D mutation
Unlike cetuximab, Peto triggers EGFR internalization and degradation through LGR5
Peto shows in vivo anti-tumor activity in other tumor types that express LGR5 such as esophageal squamous cell carcinoma, gastric carcinoma and HNSCC
Peto is currently enrolling in a phase 1 open-label, multicenter study in patients with solid tumors. Merus is planning a clinical update for the second half of 2022.
Lingus
0
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 at 5:00 PM EDT
- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types
- Zenocutuzumab observed to be well-tolerated
- Oral presentation with additional patient data at ASCO on June 5, 2022, 9:45 -11:15 a.m. CT
- Investor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT
Lees verder: ir.merus.nl/news-releases/news-releas...

In 2017 en 2018 kocht ik Merus op gemiddelde aankoop $24,00. In de jaren daarna was het koersverloop teleurstellend. Ik was blij dat ik op 2 maart dit jaar kon verkopen op $30,00. Daarna zakte heel biotech verder, en Merus naar $13,47. Zo laag dat ik gisteren aan kopen dacht. Het bericht gisteren en het koersverloop vanmiddag haalde me over: ik zit er weer in op $16,98. Beetje winst gemist maar er zit nu wel weer een grote ruimte naar boven.
DrBob
1
Ter info..
Dit bericht was van 3/6:
Does Merus N.V. (MRUS) Have the Potential to Rally 113% as Wall Street Analysts Expect?
finance.yahoo.com/news/does-merus-n-v...

En gisteren 5/6 nog meer goed nieuws:
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
finance.yahoo.com/news/merus-presents...
Pokerface
0
Gaan we dan eindelijk een keer door de 30 en blijven we daar dan ook boven? Zou wel eens lekker zijn.
fly like an eagle
0
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter that ended June 30, 2022 and provided a business update.

“At the 2022 ASCO Annual Meeting, we provided an update on our lead bispecific antibody, Zeno, which demonstrated strong efficacy across multiple tumor types, clinically meaningful duration of response and a very well tolerated safety profile. We continue to believe Zeno has the potential to be both first in class and best in class for patients with NRG1 fusion cancer,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “Additionally, we continue to make progress with our pipeline and look forward to providing an update on MCLA-129 in the second half of 2022, and Peto in the first half of 2023.”
DrBob
1
Wat een verschrikkelijk overdreven daling dit op de kwartaalcijfers, die zelf beter zijn dan geprognotiseerd; aan het toekomst perspectief is niets veranderd..
1.038 Posts, Pagina: « 1 2 3 4 5 6 ... 46 47 48 49 50 51 52 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 16 apr 2024 22:00
Koers 40,340
Verschil -0,930 (-2,25%)
Hoog 41,110
Laag 39,700
Volume 789.480
Volume gemiddeld 549.700
Volume gisteren 697.288

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront